Ideal solution or crazy bet?
In order to have new, more effective vaccines against Covid-19 as quickly as possible, the American Food and Drug Administration (FDA) intends to dispense with the results of clinical trials for some of them.
More specifically, it will be based in particular on the efficacy and tolerance data of vaccines from Pfizer/BioNTech and Moderna adapted to the Omicron BA.1 variant, which are already available, to approve - or not - those based on the BA sub-lines .4 and especially BA.5 at the start of the school year.
Since mid-June, the latter has been ultra-majority in Europe as in the United States.
Subscribe to read more
Already subscribed?
To log in
